A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SKB315 for Injection in Patients With Advanced Solid Tumors Expressing Claudin18.2
Latest Information Update: 26 Oct 2023
Price :
$35 *
At a glance
- Drugs MK 1200 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sichuan Kelun Pharmaceutical Research Institute
- 15 May 2022 New trial record